MétaCan
Menu
Back to cohort
Record W7133011077

EGFR and HER2-targeted radioimmunoconjugates for theranostic molecular imaging and Auger electron radioimmunotherapy of breast cancer

2024· dissertation· W7133011077 on OpenAlexfundno aff
Valerie Janine Facca

Bibliographic record

VenueTSpace · 2024
Typedissertation
Language
FieldMedicine
TopicRadiopharmaceutical Chemistry and Applications
Canadian institutionsnot available
FundersNatural Sciences and Engineering Research Council of CanadaUniversity of TorontoCanadian Institutes of Health ResearchTerry Fox Foundation
KeywordsRadioimmunotherapyRadionuclide therapyMolecular imagingClonogenic assayBreast cancerBiodistributionDOTASpect imagingApoptosis
DOInot available

Abstract

fetched live from OpenAlex

Overexpression of the human epidermal growth receptor 1 (HER1, EGFR) and 2 (HER2) are common in breast cancer (BC) and confer a poor prognosis. HER2-targeted pertuzumab Fab fragments were modified with hexahistidine peptides for radiolabelling with 99mTc and EGFR-targeted panitumumab with DOTA chelators for radiolabelling with 111In for SPECT imaging and Auger electron (AE) radioimmunotherapy (RIT). [99mTc]His6-pertuzumab Fab exhibited saturable specific binding to BC cells in vitro (Kd = 51.3 ± 5.2 x 10-9 M). SPECT/CT at 24 h p.i. discriminated between HER2-positive (MDA-MB-361) and negative (MDA-MB-231) human BC xenografts in NOD scid mice, with a 7-fold significant difference in tumour uptake (5.6 ± 1.4 vs. 0.8 ± 0.1 %ID/g, P<0.05). [111In]In-DOTA-panitumumab exhibited EGFR-dependent binding and nuclear localisation in MCF7 (1.5 x 104 EGFR/cell), MDA-MB-231/Luc (1.7 x 105 EGFR/cell) and MDA-MB-468 (1.3 x 106 EGFR/cell) cells, with estimated nuclear absorbed doses of 1.20 ± 0.02, 2.2 ± 0.1, and 25 ± 2 Gy, respectively for treatment with 4.4 MBq [111In]In-DOTA-panitumumab (20 nM). AE RIT with [111In]In-DOTA-panitumumab induced DNA double strand breaks, G2/M cell cycle arrest, apoptosis and reduced the clonogenic survival of EGFR-overexpressing BC cells. [111In]In-DOTA-panitumumab exhibited high uptake in MDA-MB-231/Luc tumours in NOD scid mice (18 ± 2 %ID/g) enabling clear visualization by SPECT/CT at 4 d post-injection. A single administration of [111In]In-DOTA-panitumumab (22 MBq, 15 μg) significantly delayed the growth of orthotopic MDA-MB-231/Luc mammary fat pad (MFP) tumours in NRG mice. In a model of BC recurrence after excision of 231/LM2-4 Luc+ tumours in the MFP of NRG mice, SPECT revealed high uptake of [111In]In-DOTA-panitumumab in spontaneous lung, liver and lymph node metastases. Radiation absorbed doses in metastatic lymph nodes, lungs and liver of 9.1 ± 5.7, 6.4 ± 2.0 and 10.9 ± 2.6 Gy, respectively, were estimated at the No Observable Adverse Effect Level (NOAEL; 24 MBq, 15 μg). In combination with tumour excision and fractionated X-ray radiation (5 d x 6 Gy/day) of the tumour bed, adjuvant RIT with 26 MBq (15 μg) of [111In]In-DOTA-panitumumab significantly prolonged survival from 23 to 35 d post-resection (P<0.0001). These results suggest that theranostic radiopharmaceuticals targeting EGFR and HER2 for SPECT imaging and AE RIT are promising for detection and treatment of BC.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.005

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.008
GPT teacher head0.362
Teacher spread0.354 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueTSpaceSame topicRadiopharmaceutical Chemistry and ApplicationsFrench-language works237,207